Perspectives Blog

Harlan Sonderling, CFA, Senior Healthcare Analyst

Harlan Sonderling is a senior equity analyst for fundamental research covering stocks in the healthcare sector at Columbia Management Investment Advisers, LLC (CMIA). Mr. Sonderling joined the firm in 2001 and has been a member of the investment community since 1986.
Prior to joining the firm, Mr. Sonderling was a vice president, research analyst and portfolio manager for Evergreen Investment Management. Previously, he was a vice president, research analyst and portfolio manager at Putnam Investments; vice president and equity research director at Mutual of America Life Insurance; vice president and portfolio manager at Dalton, Greiner, Hartman, Maher & Company and an equity research analyst at Sanford C. Bernstein. Mr. Sonderling began his career as an auditor and tax consultant for Arthur Andersen.
Mr. Sonderling earned a B.A. from Brown University and an M.B.A. from the Stern School of Business at New York University. He is a member of the CFA Institute and the Boston Security Analysts Society. In addition, he holds the Chartered Financial Analyst and Certified Public Accountant designations.

Death, taxes and Medicaid expansion

Harlan Sonderling, CFA, Senior Healthcare Analyst | September 8, 2014

Almost as certain as death and taxes is Medicaid expansion under ACA and the move by states toward Medicaid managed care and away from traditional fee-for-service. Medicaid managed care enrollment will expand as states transition beneficiaries from fee-for-service coverage to managed care and the “opt-in” states broaden eligibility. Medicaid coverage expansion will be a source

Predicting new drug sales is more art than science

Harlan Sonderling, CFA, Senior Healthcare Analyst | April 14, 2014

Predicting sales of new medicines is highly inaccurate and subject to significant and often costly errors. While investment analysts can draw on research tools and experience, history suggests new drug forecasting will remain more art than science. Despite the high level of uncertainty and variability in new drug forecasts, the innovative medicine industry is alive

M&A in healthcare – Out with the old, in with the new?

Harlan Sonderling, CFA, Senior Healthcare Analyst | March 31, 2014

Recently the market has been quite optimistic about merger synergy promises. History suggests investors should be diligent about analyzing acquirers’ claims around merger benefits and returns. While attractive acquisitions may lie ahead, it is critical to continue to carefully evaluate acquirers’ strategies and claims. The “old” healthcare M&A In the “old days,” pharmaceutical Company A

Specialty pharmaceuticals – The fastest growing category of healthcare spending

Harlan Sonderling, CFA, Senior Healthcare Analyst | January 27, 2014

A complex industry has developed to manage the delivery and costs of the therapeutic innovations in specialty pharma Healthcare payers are focused on managing specialty pharma spending, their most rapidly growing medical cost The accelerating pace of change and disruptive therapeutic advances create significant opportunities across healthcare delivery Pharmaceuticals are central to the effort to